Search

Your search keyword '"El-Khouly, Fatima"' showing total 20 results
Start Over Author "El-Khouly, Fatima"
20 results on '"El-Khouly, Fatima"'

3. ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

Author

Elyashiv, Osnat, Ledermann, Jonathan, Parmar, Gita, Farrelly, Laura, Counsell, Nicholas, Feeney, Amanda, El-Khouly, Fatima, Macdonald, Ian, Neto, Andreia, Arthur-Darkwa, Esther, Burnett, Eva, Jayson, Gordon C, Mileshkin, Linda, Gourley, Charlie, and Nicum, Shibani

Published
2021
Full Text
View/download PDF

4. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

Author

Kristeleit, Rebecca, Davidenko, Irina, Shirinkin, Vadim, El-Khouly, Fatima, Bondarenko, Igor, Goodheart, Michael J., Gorbunova, Vera, Penning, Carol A., Shi, Jack G., Liu, Xiangdong, Newton, Robert C., Zhao, Yufan, Maleski, Janet, Leopold, Lance, and Schilder, Russell J.

Published
2017
Full Text
View/download PDF

5. 2022-RA-1310-ESGO Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer

Author

Sun, Li, primary, Sobocan, Monika, additional, Rodriguez, Isabel V, additional, Wei, Xia, additional, Kalra, Ashwin, additional, Oxley, Samuel, additional, Sideris, Michail, additional, Morgan, Robert D, additional, Chandrasekaran, Dhivya, additional, Rust, Kelly, additional, Spiliopoulou, Pavlina, additional, Miller, Rowan E, additional, Crusz, Shanthini M, additional, Lockley, Michelle, additional, Singh, Naveena, additional, Faruqi, Asma, additional, Casey, Laura, additional, Brockbank, Elly, additional, Phadnis, Saurabh, additional, Mills-Baldock, Tina, additional, El-Khouly, Fatima, additional, Jenkins, Lucy A, additional, Wallace, Andrew, additional, Ahmed, Munaza, additional, Kumar, Ajith, additional, Swisher, Elizabeth M, additional, Gourley, Charlie, additional, Norquist, Barbara M, additional, Gareth Evans, D, additional, Legood, Rosa, additional, and Manchanda, Ranjit, additional

Published
2022
Full Text
View/download PDF

6. Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study

Author

Chandrasekaran, Dhivya, primary, Sobocan, Monika, additional, Blyuss, Oleg, additional, Miller, Rowan E., additional, Evans, Olivia, additional, Crusz, Shanthini M., additional, Mills-Baldock, Tina, additional, Sun, Li, additional, Hammond, Rory F. L., additional, Gaba, Faiza, additional, Jenkins, Lucy A., additional, Ahmed, Munaza, additional, Kumar, Ajith, additional, Jeyarajah, Arjun, additional, Lawrence, Alexandra C., additional, Brockbank, Elly, additional, Phadnis, Saurabh, additional, Quigley, Mary, additional, El Khouly, Fatima, additional, Wuntakal, Rekha, additional, Faruqi, Asma, additional, Trevisan, Giorgia, additional, Casey, Laura, additional, Burghel, George J., additional, Schlecht, Helene, additional, Bulman, Michael, additional, Smith, Philip, additional, Bowers, Naomi L., additional, Legood, Rosa, additional, Lockley, Michelle, additional, Wallace, Andrew, additional, Singh, Naveena, additional, Evans, D. Gareth, additional, and Manchanda, Ranjit, additional

Published
2021
Full Text
View/download PDF

8. ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

Author

Elyashiv, Osnat, primary, Ledermann, Jonathan, additional, Parmar, Gita, additional, Farrelly, Laura, additional, Counsell, Nicholas, additional, Feeney, Amanda, additional, El-Khouly, Fatima, additional, Macdonald, Ian, additional, Neto, Andreia, additional, Arthur-Darkwa, Esther, additional, Burnett, Eva, additional, Jayson, Gordon C, additional, Mileshkin, Linda, additional, Gourley, Charlie, additional, and Nicum, Shibani, additional

Published
2020
Full Text
View/download PDF

10. Prognostic Factors for Survival among Patients with Small Bowel Neuroendocrine Tumours Associated with Mesenteric Desmoplasia

Author

Laskaratos, Faidon Marios, primary, Diamantopoulos, Leonidas, additional, Walker, Martin, additional, Walton, Henry, additional, Khalifa, Mohamed, additional, El-Khouly, Fatima, additional, Koffas, Apostolos, additional, Demetriou, George, additional, Caplin, Martyn, additional, Toumpanakis, Christos, additional, and Mandair, Dalvinder, additional

Published
2018
Full Text
View/download PDF

11. Phase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors.

Author

Zubairi, Ishtiaq Husain, primary, Dean, Emma Jane, additional, Molife, L Rhoda, additional, Lopez, Juanita Suzanne, additional, Ranson, Malcolm, additional, El-Khouly, Fatima, additional, Savulsky, Claudio Isaac, additional, Reyderman, Larisa, additional, Jia, Yan, additional, Hutton, Emily, additional, Morrison, Rosemary, additional, Sweeting, Lorna, additional, Greystoke, Alastair, additional, Barriuso, Jorge, additional, Kristeleit, Rebecca Sophie, additional, and Evans, T.R. Jeffry, additional

Published
2016
Full Text
View/download PDF

13. Phase 1/2 study of oral rucaparib: Final phase 1 results.

Author

Kristeleit, Rebecca Sophie, primary, Burris, Howard A., additional, LoRusso, Patricia, additional, Patel, Manish R., additional, Asghar, Uzma Saddia, additional, El-Khouly, Fatima, additional, Calvert, Alan Hilary, additional, Infante, Jeffrey R., additional, Hilton, John Frederick, additional, Tolaney, Sara M., additional, Kittaneh, Muaiad, additional, Giordano, Heidi, additional, Borrow, Jennifer, additional, Jaw-Tsai, Sarah S., additional, and Shapiro, Geoffrey, additional

Published
2014
Full Text
View/download PDF

14. Phase I/IIa trial of the novel microtubule inhibitor BAL101553 in advanced solid tumors: Phase I completed.

Author

Molife, L Rhoda, primary, Imseeh, Georgios, additional, Capelan, Marta, additional, El-Khouly, Fatima, additional, Cresti, Nicola, additional, Smith, Alan David, additional, Averion, Dexter, additional, Md. Haris, Noor, additional, Stimpson, Sarah Jane, additional, Gumbleton, Todd, additional, Lane, Heidi A, additional, Bachmann, Felix, additional, Schmitt-Hoffmann, Anne, additional, Tzankov, Alexandar, additional, Hannah, Alison L., additional, Anderson, Stephanie, additional, Bette, Ullrich, additional, Calvert, Alan Hilary, additional, Plummer, Ruth, additional, and Kristeleit, Rebecca Sophie, additional

Published
2014
Full Text
View/download PDF

15. The Impact of Folfirinox Chemotherapy on the Treatment Pattern of Patients with Pancreas Cancer Seen at a Tertiary Referral Centre in the UK

Author

Julve Maximilian, Goldstein Robert, Chopra Neha, Gillmore Roopinder, Thirlwell Christina, El-Khouly Fatima, Mayer Astrid, and Meyer Tim

Subjects
Chemotherapy, medicine.medical_specialty, business.industry, FOLFIRINOX, Tertiary referral centre, medicine.medical_treatment, General surgery, Cancer, Hematology, medicine.disease, Chemotherapy regimen, Patient referral, medicine.anatomical_structure, Oncology, Pancreatic cancer, medicine, Pancreas, business
Published
2014

19. Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.

Author

Manchanda R, Sun L, Sobocan M, Rodriguez IV, Wei X, Kalra A, Oxley S, Sideris M, Fierheller CT, Morgan RD, Chandrasekaran D, Rust K, Spiliopoulou P, Miller RE, Crusz SM, Lockley M, Singh N, Faruqi A, Casey L, Brockbank E, Phadnis S, Mills-Baldock T, El-Khouly F, Jenkins LA, Wallace A, Ahmed M, Kumar A, Swisher EM, Gourley C, Norquist BM, Evans DG, and Legood R

Subjects
Humans, Female, Genetic Predisposition to Disease, BRCA2 Protein genetics, BRCA1 Protein genetics, Middle Aged, United States epidemiology, Quality-Adjusted Life Years, Poly(ADP-ribose) Polymerase Inhibitors therapeutic use, Poly(ADP-ribose) Polymerase Inhibitors economics, RNA Helicases genetics, Adult, United Kingdom epidemiology, Fanconi Anemia Complementation Group Proteins genetics, DNA-Binding Proteins, Cost-Benefit Analysis, Genetic Testing economics, Genetic Testing methods, Germ-Line Mutation, Carcinoma, Ovarian Epithelial genetics, Carcinoma, Ovarian Epithelial economics, Carcinoma, Ovarian Epithelial diagnosis, Carcinoma, Ovarian Epithelial drug therapy, Carcinoma, Ovarian Epithelial pathology, Ovarian Neoplasms genetics, Ovarian Neoplasms drug therapy, Ovarian Neoplasms diagnosis, Ovarian Neoplasms economics
Abstract

Background: Parallel panel germline and somatic genetic testing of all patients with ovarian cancer (OC) can identify more pathogenic variants (PVs) that would benefit from PARP inhibitor (PARPi) therapy, and allow for precision prevention in unaffected relatives with PVs. In this study, we estimate the cost-effectiveness and population impact of parallel panel germline and somatic BRCA testing of all patients with OC incorporating PARPi therapy in the United Kingdom and the United States compared with clinical criteria/family history (FH)-based germline BRCA testing. We also evaluate the cost-effectiveness of multigene panel germline testing alone., Methods: Microsimulation cost-effectiveness modeling using data from 2,391 (UK: n=1,483; US: n=908) unselected, population-based patients with OC was used to compare lifetime costs and effects of panel germline and somatic BRCA testing of all OC cases (with PARPi therapy) (strategy A) versus clinical criteria/FH-based germline BRCA testing (strategy B). Unaffected relatives with germline BRCA1/BRCA2/RAD51C/RAD51D/BRIP1 PVs identified through cascade testing underwent appropriate OC and breast cancer (BC) risk-reduction interventions. We also compared the cost-effectiveness of multigene panel germline testing alone (without PARPi therapy) versus strategy B. Unaffected relatives with PVs could undergo risk-reducing interventions. Lifetime horizon with payer/societal perspectives, along with probabilistic/one-way sensitivity analyses, are presented. Incremental cost-effectiveness ratio (ICER) and incremental cost per quality-adjusted life year (QALY) gained were compared with £30,000/QALY (UK) and $100,000/QALY (US) thresholds. OC incidence, BC incidence, and prevented deaths were estimated., Results: Compared with clinical criteria/FH-based BRCA testing, BRCA1/BRCA2/RAD51C/RAD51D/BRIP1 germline testing and BRCA1/BRCA2 somatic testing of all patients with OC incorporating PARPi therapy had a UK ICER of £51,175/QALY (payer perspective) and £50,202/QALY (societal perspective) and a US ICER of $175,232/QALY (payer perspective) and $174,667/QALY (societal perspective), above UK/NICE and US cost-effectiveness thresholds in the base case. However, strategy A becomes cost-effective if PARPi costs decrease by 45% to 46% or if overall survival with PARPi reaches a hazard ratio of 0.28. Unselected panel germline testing alone (without PARPi therapy) is cost-effective, with payer-perspective ICERs of £11,291/QALY or $68,808/QALY and societal-perspective ICERs of £6,923/QALY or $65,786/QALY. One year's testing could prevent 209 UK BC/OC cases and 192 deaths, and 560 US BC/OC cases and 460 deaths., Conclusions: Unselected panel germline and somatic BRCA testing can become cost-effective, with a 45% to 46% reduction in PARPi costs. Regarding germline testing, unselected panel germline testing is highly cost-effective and should replace BRCA testing alone.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results